Samples Available for Recipient Only. Samples Available for Recipient and Donor

Transcription

1 Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples, recipient only samples and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program Available Only Number of patients Source of data CRF (58) 5546 (54) 4219 (62) TED (42) 4768 (46) 2620 (38) Number of centers Disease at transplant AML (34) 3664 (36) 2205 (32) ALL 5515 (15) 1422 (14) 1148 (17) Other leukemia 1301 (4) 321 (3) 222 (3) CML 3198 (9) 852 (8) 715 (10) MDS 5911 (16) 1784 (17) 905 (13) Other acute leukemia 382 (1) 116 (1) 70 (1) NHL 3544 (10) 934 (9) 560 (8) Hodgkins Lymphoma 795 (2) 160 (2) 122 (2) Plasma Cell Disorders, MM 761 (2) 220 (2) 107 (2) Other malignancies 54 (<1) 13 (<1) 17 (<1) Breast cancer 7 (<1) 3 (<1) 1 (<1) SAA 1180 (3) 292 (3) 276 (4) Inherited abnormalities erythrocyte diff fxn 655 (2) 176 (2) 128 (2) SCIDs 633 (2) 182 (2) 183 (3) Inherited abnormalities of platelets 38 (<1) 9 (<1) 9 (<1) Inherited disorders of metabolism 260 (1) 62 (1) 79 (1) Histiocytic disorders 329 (1) 82 (1) 71 (1) Autoimmune disorders 16 (<1) 7 (<1) 3 (<1) Other 42 (<1) 15 (<1) 18 (<1) AML Disease status at transplant CR (50) 1847 (50) 955 (43) CR (20) 743 (20) 468 (21) CR (2) 70 (2) 50 (2) Advanced or active disease 3295 (26) 968 (26) 685 (31) Missing 143 (1) 36 (1) 43 (2) ALL Disease status at transplant CR (47) 702 (49) 461 (40) CR (30) 389 (27) 341 (30) CR (8) 118 (8) 111 (10) Advanced or active disease 782 (14) 199 (14) 203 (18) Missing 44 (1) 14 (1) 31 (3) MDS Disease status at transplant Early 1220 (21) 316 (18) 211 (24) Advanced 4193 (71) 1342 (76) 559 (63) Missing 457 (8) 113 (6) 124 (14)

2 Available Only NHL Disease status at transplant CR1 443 (13) 149 (16) 57 (10) CR2 655 (19) 166 (18) 93 (17) CR (9) 82 (9) 47 (8) PR 431 (12) 108 (12) 78 (14) Advanced 1637 (47) 412 (44) 273 (49) Missing 49 (1) 9 (1) 9 (2) Recipient age at transplant 0-9 years 3347 (9) 824 (8) 894 (13) years 3468 (9) 852 (8) 813 (12) years 3987 (11) 1080 (10) 853 (12) years 4433 (12) 1125 (11) 891 (13) years 5877 (16) 1608 (16) 1098 (16) years 7768 (21) 2121 (21) 1193 (17) years 7092 (19) 2249 (22) 963 (14) 70+ years 1190 (3) 455 (4) 134 (2) Median (Range) 46 (0-84) 48 (0-79) 40 (0-79) Recipient race/ethnicity Caucasian, non-hispanic (85) 8594 (85) 5170 (83) African-American, non-hispanic 1699 (5) 433 (4) 294 (5) Asian, non-hispanic 795 (2) 342 (3) 231 (4) Pacific islander, non-hispanic 48 (<1) 15 (<1) 12 (<1) Native American, non-hispanic 141 (<1) 47 (<1) 23 (<1) Hispanic 2586 (7) 630 (6) 454 (7) Other 44 (<1) 25 (<1) 21 (<1) Unknown 858 (N/A) 228 (N/A) 634 (N/A) Recipient sex Male (58) 6080 (59) 4047 (59) Female (42) 4234 (41) 2792 (41) Karnofsky score (33) 3574 (35) 2046 (30) (63) 6195 (60) 4272 (62) Missing 1477 (4) 545 (5) 521 (8) HLA-A B DRB1 groups - low resolution <=3/6 21 (<1) 24 (<1) 1 (<1) 4/6 205 (1) 72 (1) 28 (<1) 5/ (14) 1300 (14) 972 (15) 6/ (85) 7639 (85) 5303 (84) Unknown 395 (N/A) 1279 (N/A) 535 (N/A) High-resolution HLA matches available out of 8 <=5/8 834 (2) 63 (1) 27 (1) 6/ (5) 103 (2) 117 (3) 7/ (21) 1268 (19) 932 (23) 8/ (73) 5258 (79) 2966 (73) Unknown 1171 (N/A) 3622 (N/A) 2797 (N/A) HLA-DPB1 Match Double allele mismatch 8841 (30) 491 (25) 283 (28) Single allele mismatch (54) 1000 (51) 525 (52)

3 Available Only Full allele matched 4560 (16) 479 (24) 199 (20) Unknown 7923 (N/A) 8344 (N/A) 5832 (N/A) High resolution release score No 8669 (23) (98) 6661 (97) Yes (77) 209 (2) 178 (3) KIR typing available No (63) (99) 6798 (99) Yes (37) 125 (1) 41 (1) Graft type Marrow (38) 3736 (36) 3221 (47) PBSC (62) 6482 (63) 3615 (53) BM+PBSC 8 (<1) 6 (<1) 2 (<1) BM+UCB 0 1 (<1) 0 PBSC+UCB 12 (<1) 89 (1) 1 (<1) Conditioning regimen Myeloablative (65) 6436 (62) 4690 (69) RIC/Nonmyeloablative (35) 3836 (37) 2069 (30) TBD 173 (<1) 42 (<1) 80 (1) age at donation To Be Determined/NA 157 (<1) 1252 (12) 55 (1) 0-9 years 10 (<1) 15 (<1) years 1017 (3) 289 (3) 145 (2) years (43) 4026 (39) 2498 (37) years (29) 2647 (26) 2162 (32) years 7021 (19) 1579 (15) 1498 (22) 50+ years 2142 (6) 506 (5) 481 (7) Median (Range) 31 (0-69) 31 (0-109) 33 (18-67) /Recipient CMV serostatus +/ (25) 2771 (28) 1656 (26) +/ (12) 1331 (13) 847 (13) -/ (33) 3023 (31) 2099 (33) -/ (30) 2744 (28) 1845 (29) CB - recipient (<1) 0 CB - recipient (<1) 0 CB - recipient CMV unknown 0 1 (<1) 0 Unknown 530 (N/A) 439 (N/A) 392 (N/A) GvHD Prophylaxis Ex vivo T-cell depletion 1082 (3) 269 (3) 300 (4) CD34 selection 657 (2) 264 (3) 104 (2) Tacrolimus + MMF +- others 4438 (12) 1066 (10) 578 (8) Tacrolimus + MTX +- others (except MMF) (43) 4544 (44) 1890 (28) Tacrolimus + others (except MTX, MMF) 1935 (5) 655 (6) 270 (4) Tacrolimus alone 907 (2) 282 (3) 118 (2) CSA + MMF +- others (except Tacrolimus) 2570 (7) 564 (5) 558 (8) CSA + MTX +- others (except Tacrolimus, MMF) 6442 (17) 1655 (16) 2118 (31) CSA + others (except Tacrolimus, MTX, MMF) 981 (3) 296 (3) 284 (4) CSA alone 462 (1) 115 (1) 267 (4) Other GVHD prophylaxis 687 (2) 199 (2) 116 (2)

4 Available Only Missing 1106 (3) 405 (4) 236 (3) /Recipient sex match Male-Male (42) 4100 (40) 2714 (40) Male-Female 9313 (25) 2474 (24) 1578 (23) Female-Male 6279 (17) 1878 (18) 1315 (19) Female-Female 6055 (16) 1662 (16) 1197 (18) CB - recipient M 5 (<1) 49 (<1) 0 CB - recipient F 7 (<1) 41 (<1) 1 (<1) Unknown 135 (N/A) 110 (N/A) 34 (N/A) Year of transplant (1) 45 (<1) 85 (1) (5) 449 (4) 611 (9) (8) 1112 (11) 894 (13) (13) 988 (10) 1436 (21) (25) 1853 (18) 1404 (21) (35) 3618 (35) 1723 (25) (13) 2249 (22) 686 (10) Follow-up among survivors, Months N Eval Median (Range) 50 (0-344) 36 (0-318) 50 (1-337)

5 Unrelated Cord Blood Transplant Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired, recipient only and cord blood only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006-recipient only), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program Available Only Number of patients Source of data CRF 3976 (77) 731 (76) 750 (66) TED 1202 (23) 228 (24) 390 (34) Number of centers Disease at transplant AML 2031 (39) 339 (35) 379 (33) ALL 1105 (21) 201 (21) 267 (23) Other leukemia 99 (2) 16 (2) 19 (2) CML 131 (3) 23 (2) 28 (2) MDS 512 (10) 92 (10) 100 (9) Other acute leukemia 83 (2) 13 (1) 20 (2) NHL 288 (6) 52 (5) 67 (6) Hodgkins Lymphoma 32 (1) 4 (<1) 9 (1) Plasma Cell Disorders, MM 9 (<1) 2 (<1) 2 (<1) Other malignancies 7 (<1) 0 1 (<1) SAA 89 (2) 23 (2) 20 (2) Inherited abnormalities erythrocyte diff fxn 142 (3) 40 (4) 30 (3) SCIDs 224 (4) 54 (6) 81 (7) Inherited abnormalities of platelets 14 (<1) 1 (<1) 4 (<1) Inherited disorders of metabolism 300 (6) 75 (8) 77 (7) Histiocytic disorders 90 (2) 22 (2) 30 (3) Autoimmune disorders 10 (<1) 0 1 (<1) Other 12 (<1) 2 (<1) 5 (<1) AML Disease status at transplant CR (50) 182 (54) 197 (52) CR2 589 (29) 93 (27) 96 (25) CR3+ 49 (2) 2 (1) 13 (3) Advanced or active disease 375 (18) 61 (18) 71 (19) Missing 8 (<1) 1 (<1) 2 (1) ALL Disease status at transplant CR1 498 (45) 84 (42) 114 (43) CR2 417 (38) 80 (40) 96 (36) CR (11) 26 (13) 29 (11) Advanced or active disease 73 (7) 11 (5) 27 (10) Missing (<1) MDS Disease status at transplant Early 166 (32) 24 (27) 48 (48) Advanced 312 (61) 62 (69) 43 (43) Missing 33 (6) 4 (4) 8 (8) NHL Disease status at transplant

6 Available Only CR1 51 (18) 5 (10) 17 (26) CR2 60 (21) 12 (23) 14 (21) CR3+ 20 (7) 7 (13) 7 (11) PR 57 (20) 7 (13) 11 (17) Advanced 97 (34) 21 (40) 15 (23) Missing (3) Recipient age at transplant 0-9 years 1504 (29) 379 (40) 425 (37) years 703 (14) 102 (11) 155 (14) years 505 (10) 63 (7) 89 (8) years 516 (10) 77 (8) 106 (9) years 567 (11) 89 (9) 106 (9) years 700 (14) 115 (12) 141 (12) years 594 (11) 116 (12) 111 (10) 70+ years 89 (2) 18 (2) 7 (1) Median (Range) 28 (0-81) 20 (0-75) 19 (0-74) Recipient race/ethnicity Caucasian, non-hispanic 2927 (59) 563 (62) 617 (61) African-American, non-hispanic 723 (15) 131 (14) 133 (13) Asian, non-hispanic 305 (6) 60 (7) 73 (7) Pacific islander, non-hispanic 23 (<1) 2 (<1) 11 (1) Native American, non-hispanic 29 (1) 4 (<1) 13 (1) Hispanic 925 (19) 151 (17) 170 (17) Unknown 246 (N/A) 48 (N/A) 123 (N/A) Recipient sex Male 2838 (55) 561 (58) 656 (58) Female 2340 (45) 398 (42) 484 (42) Karnofsky score (26) 229 (24) 270 (24) (72) 694 (72) 824 (72) Missing 113 (2) 36 (4) 46 (4) HLA-A B DRB1 groups - low resolution <=3/6 68 (1) 28 (3) 6 (1) 4/ (42) 379 (41) 420 (37) 5/ (44) 387 (42) 536 (48) 6/6 644 (13) 133 (14) 166 (15) Unknown 44 (N/A) 32 (N/A) 12 (N/A) High-resolution HLA matches available out of 8 <=5/ (56) 392 (57) 491 (54) 6/ (24) 155 (23) 215 (24) 7/8 608 (13) 85 (12) 137 (15) 8/8 306 (7) 52 (8) 69 (8) Unknown 556 (N/A) 275 (N/A) 228 (N/A) HLA-DPB1 Match Double allele mismatch 815 (40) 45 (43) 50 (41) Single allele mismatch 1043 (51) 48 (46) 57 (47) Full allele matched 187 (9) 11 (11) 14 (12) Unknown 3133 (N/A) 855 (N/A) 1019 (N/A)

7 Available Only High resolution release score No 3325 (64) 907 (95) 1118 (98) Yes 1853 (36) 52 (5) 22 (2) KIR typing available No 3575 (69) 953 (99) 1119 (98) Yes 1603 (31) 6 (1) 21 (2) Cord blood number of units (64) (76) (36) (24) 3 2 (<1) 0 0 Unknown 0 (N/A) 959 (N/A) 0 (N/A) Graft type UCB 4946 (96) 858 (89) 1088 (95) BM+UCB 1 (<1) 1 (<1) 0 PBSC+UCB 231 (4) 100 (10) 52 (5) Conditioning regimen Myeloablative 3490 (67) 618 (64) 765 (67) RIC/Nonmyeloablative 1677 (32) 341 (36) 372 (33) TBD 11 (<1) 0 3 (<1) age at donation To Be Determined/NA 47 (1) 29 (3) 9 (1) 0-9 years 4766 (92) 761 (79) 1053 (92) years 222 (4) 84 (9) 47 (4) years 44 (1) 28 (3) 6 (1) years 40 (1) 29 (3) 12 (1) years 25 (<1) 10 (1) 4 (<1) 50+ years 34 (1) 18 (2) 9 (1) Median (Range) 3 (-0-72) 4 (-0-73) 3 (0-67) /Recipient CMV serostatus +/ (24) 195 (20) 242 (21) +/- 526 (10) 90 (9) 106 (9) -/+ 971 (19) 182 (19) 206 (18) -/- 668 (13) 119 (12) 159 (14) CB - recipient (19) 198 (21) 219 (19) CB - recipient (13) 160 (17) 176 (15) CB - recipient CMV unknown 80 (2) 15 (2) 32 (3) GvHD Prophylaxis Ex vivo T-cell depletion 25 (<1) 11 (1) 4 (<1) CD34 selection 175 (3) 72 (8) 40 (4) Tacrolimus + MMF +- others 1366 (26) 239 (25) 178 (16) Tacrolimus + MTX +- others (except MMF) 188 (4) 40 (4) 51 (4) Tacrolimus + others (except MTX, MMF) 205 (4) 37 (4) 46 (4) Tacrolimus alone 119 (2) 19 (2) 20 (2) CSA + MMF +- others (except Tacrolimus) 2523 (49) 403 (42) 573 (50) CSA + MTX +- others (except Tacrolimus, MMF) 92 (2) 21 (2) 30 (3) CSA + others (except Tacrolimus, MTX, MMF) 299 (6) 87 (9) 134 (12) CSA alone 52 (1) 12 (1) 40 (4) Other GVHD prophylaxis 109 (2) 14 (1) 14 (1)

8 Available Only Missing 25 (<1) 4 (<1) 10 (1) /Recipient sex match CB - recipient M 2838 (55) 561 (58) 655 (57) CB - recipient F 2340 (45) 398 (42) 484 (42) CB - recipient sex unknown (<1) Year of transplant (<1) 4 (<1) (2) 69 (7) 25 (2) (36) 256 (27) 400 (35) (48) 409 (43) 539 (47) (14) 223 (23) 172 (15) Follow-up among survivors, Months N Eval Median (Range) 51 (1-149) 36 (1-191) 49 (1-193)

9 Related HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired, recipient only and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program Available Only Number of patients Source of data CRF 2203 (39) 263 (31) 149 (40) TED 3512 (61) 584 (69) 222 (60) Number of centers Disease at transplant AML 1859 (33) 286 (34) 111 (30) ALL 900 (16) 164 (19) 54 (15) Other leukemia 139 (2) 25 (3) 18 (5) CML 203 (4) 19 (2) 13 (4) MDS 929 (16) 126 (15) 51 (14) Other acute leukemia 76 (1) 14 (2) 3 (1) NHL 604 (11) 80 (9) 55 (15) Hodgkins Lymphoma 126 (2) 18 (2) 17 (5) Plasma Cell Disorders, MM 174 (3) 29 (3) 13 (4) Other malignancies 15 (<1) 0 0 Breast cancer 1 (<1) 0 0 SAA 248 (4) 27 (3) 11 (3) Inherited abnormalities erythrocyte diff fxn 277 (5) 39 (5) 16 (4) SCIDs 105 (2) 17 (2) 6 (2) Inherited abnormalities of platelets 9 (<1) 0 0 Inherited disorders of metabolism 8 (<1) 0 0 Histiocytic disorders 30 (1) 2 (<1) 2 (1) Autoimmune disorders 4 (<1) 0 0 Other 8 (<1) 1 (<1) 1 (<1) AML Disease status at transplant CR (61) 180 (63) 68 (61) CR2 293 (16) 31 (11) 10 (9) CR3+ 23 (1) 4 (1) 0 Advanced or active disease 406 (22) 69 (24) 31 (28) Missing 7 (<1) 2 (1) 2 (2) ALL Disease status at transplant CR1 566 (63) 107 (65) 38 (70) CR2 247 (27) 33 (20) 10 (19) CR3+ 39 (4) 5 (3) 1 (2) Advanced or active disease 48 (5) 19 (12) 5 (9) MDS Disease status at transplant Early 164 (18) 15 (12) 5 (10) Advanced 735 (79) 108 (86) 44 (86) Missing 30 (3) 3 (2) 2 (4) NHL Disease status at transplant

10 Available Only CR1 96 (16) 18 (23) 7 (13) CR2 120 (20) 13 (16) 10 (18) CR3+ 68 (11) 6 (8) 2 (4) PR 58 (10) 11 (14) 5 (9) Advanced 257 (43) 31 (39) 31 (56) Missing 1 (<1) 0 0 Recipient age at transplant 0-9 years 537 (9) 65 (8) 25 (7) years 595 (10) 60 (7) 25 (7) years 460 (8) 91 (11) 30 (8) years 442 (8) 75 (9) 32 (9) years 807 (14) 118 (14) 53 (14) years 1379 (24) 200 (24) 96 (26) years 1315 (23) 214 (25) 100 (27) 70+ years 180 (3) 24 (3) 10 (3) Median (Range) 50 (0-78) 51 (0-76) 53 (0-74) Recipient race/ethnicity Caucasian, non-hispanic 3687 (67) 460 (58) 244 (69) African-American, non-hispanic 654 (12) 84 (11) 39 (11) Asian, non-hispanic 259 (5) 69 (9) 22 (6) Pacific islander, non-hispanic 22 (<1) 3 (<1) 0 Native American, non-hispanic 22 (<1) 1 (<1) 0 Hispanic 865 (16) 176 (22) 51 (14) Unknown 206 (N/A) 54 (N/A) 15 (N/A) Recipient sex Male 3351 (59) 505 (60) 222 (60) Female 2364 (41) 342 (40) 149 (40) Karnofsky score (34) 349 (41) 148 (40) (63) 479 (57) 205 (55) Missing 137 (2) 19 (2) 18 (5) Graft type Marrow 1568 (27) 200 (24) 104 (28) PBSC 4123 (72) 640 (76) 263 (71) BM+PBSC 5 (<1) 3 (<1) 0 BM+UCB 19 (<1) 4 (<1) 1 (<1) PBSC+UCB (1) Conditioning regimen Myeloablative 3367 (59) 496 (59) 201 (54) RIC/Nonmyeloablative 2314 (40) 346 (41) 164 (44) TBD 34 (1) 5 (1) 6 (2) age at donation To Be Determined/NA 28 (<1) 1 (<1) 3 (1) 0-9 years 395 (7) 39 (5) 16 (4) years 540 (9) 73 (9) 25 (7) years 691 (12) 113 (13) 40 (11) years 692 (12) 124 (15) 63 (17) years 950 (17) 143 (17) 48 (13)

11 Available Only 50+ years 2419 (42) 354 (42) 176 (47) Median (Range) 46 (0-81) 45 (0-79) 48 (0-76) /Recipient CMV serostatus +/ (42) 412 (50) 163 (46) +/- 606 (11) 58 (7) 44 (12) -/ (25) 194 (23) 83 (23) -/ (23) 166 (20) 68 (19) Unknown 82 (N/A) 17 (N/A) 13 (N/A) GvHD Prophylaxis Ex-vivo T-cell depletion 64 (1) 16 (2) 3 (1) CD34 selection 75 (1) 26 (3) 7 (2) Post-CY + other(s) 924 (16) 141 (17) 61 (16) Post-CY alone 28 (<1) 8 (1) 3 (1) TAC + MMF +- other(s) (except post-cy) 673 (12) 57 (7) 26 (7) TAC + MTX +- other(s) (except MMF, post-cy) 2418 (42) 312 (37) 179 (48) TAC + other(s) (except MMF, MTX, post-cy) 544 (10) 187 (22) 44 (12) TAC alone 50 (1) 8 (1) 1 (<1) CSA + MMF +- other(s) (except post-cy) 150 (3) 11 (1) 4 (1) CSA + MTX +- other(s) (except MMF, post-cy) 482 (8) 48 (6) 25 (7) CSA + other(s) (except MMF, MTX, post-cy) 55 (1) 9 (1) 2 (1) CSA alone 52 (1) 7 (1) 1 (<1) Other(s) 88 (2) 7 (1) 5 (1) Missing 112 (2) 10 (1) 10 (3) /Recipient sex match Male-Male 1842 (32) 308 (36) 133 (36) Male-Female 1247 (22) 163 (19) 73 (20) Female-Male 1492 (26) 193 (23) 88 (24) Female-Female 1113 (19) 178 (21) 73 (20) CB - recipient M 15 (<1) 3 (<1) 1 (<1) CB - recipient F 4 (<1) 1 (<1) 3 (1) Unknown 2 (N/A) 1 (N/A) 0 (N/A) Year of transplant (9) 48 (6) 38 (10) (56) 452 (53) 203 (55) (35) 347 (41) 130 (35) Follow-up among survivors, Months N Eval Median (Range) 25 (1-123) 23 (1-121) 25 (3-109)